Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 233 entries
Sorted by: Best Match Show Resources per page
Evaluating sustainability education: lessons from international development experience

Asset based approaches STEM training

Uitto JI.
GSID: N0IHWSS03Y0J
PH Koehn, JI Uitto - Higher Education, 2014 - Springer

… of higher-education curricular, research, and community-outreach programs devoted to sustainability based on critical review of quantitative- and qualitative-evaluation methods and on …

Cite
Koehn, P. H., & Uitto, J. I. (2014). Evaluating sustainability education: lessons from international development experience. Higher Education, 67, 621-635.
Koehn, Peter H., and Juha I. Uitto. "Evaluating sustainability education: lessons from international development experience." Higher Education 67 (2014): 621-635.
Copy Download .nbib Format: MLA
The benefits of international postdoctoral research fellowships: a personal perspective

postdoctoral

Uitto J.
GSID: qS5m2F5ZHj4J
J Uitto - The Journal of Investigative Dermatology, 2013 - scholar.archive.org

… think of my own early experiences as a young postdoctoral fellow. The cultural differences, … own postdoctoral fellowship in the United States. However, it is clear that postdoctoral training …

Cite
Uitto, J. (2013). The benefits of international postdoctoral research fellowships: a personal perspective. The Journal of Investigative Dermatology, 133(10), 2301.
Uitto, Jouni. "The benefits of international postdoctoral research fellowships: a personal perspective." The Journal of Investigative Dermatology 133.10 (2013): 2301.
Copy Download .nbib Format: MLA
Structural Changes in 2D BiSe Bilayers as n Increases in (BiSe).

ACS nano

Mitchson G, Hadland E, Göhler F, Wanke M, Esters M, Ditto J, Bigwood E, Ta K, Hennig RG, Seyller T, Johnson DC.
PMID: 27673390
ACS Nano. 2016 Oct 25;10(10):9489-9499. doi: 10.1021/acsnano.6b04606. Epub 2016 Sep 28.

(BiSe)

Cite
Mitchson G, Hadland E, Göhler F, et al. Structural Changes in 2D BiSe Bilayers as n Increases in (BiSe). ACS Nano. 2016;10(10):9489-9499doi: 10.1021/acsnano.6b04606.
Mitchson, G., Hadland, E., Göhler, F., Wanke, M., Esters, M., Ditto, J., Bigwood, E., Ta, K., Hennig, R. G., Seyller, T., & Johnson, D. C. (2016). Structural Changes in 2D BiSe Bilayers as n Increases in (BiSe). ACS nano, 10(10), 9489-9499. https://doi.org/10.1021/acsnano.6b04606
Mitchson, Gavin, et al. "Structural Changes in 2D BiSe Bilayers as n Increases in (BiSe)." ACS nano vol. 10,10 (2016): 9489-9499. doi: https://doi.org/10.1021/acsnano.6b04606
Mitchson G, Hadland E, Göhler F, Wanke M, Esters M, Ditto J, Bigwood E, Ta K, Hennig RG, Seyller T, Johnson DC. Structural Changes in 2D BiSe Bilayers as n Increases in (BiSe). ACS Nano. 2016 Oct 25;10(10):9489-9499. doi: 10.1021/acsnano.6b04606. Epub 2016 Sep 28. PMID: 27673390.
Copy Download .nbib Format: NLM
Efficacy of HCV treatment in Poland at the turn of the interferon era - the EpiTer study.

Clinical and experimental hepatology

Flisiak R, Pogorzelska J, Berak H, Horban A, Orłowska I, Simon K, Tuchendler E, Madej G, Piekarska A, Jabłkowski M, Deroń Z, Mazur W, Kaczmarczyk M, Janczewska E, Pisula A, Smykał J, Nowak K, Matukiewicz M, Halota W, Wernik J, Sikorska K, Mozer-Lisewska I, Rozpłochowski B, Garlicki A, Tomasiewicz K, Krzowska-Firych J, Baka-Ćwierz B, Kryczka W, Zarębska-Michaluk D, Olszok I, Boroń-Kaczmarska A, Sobala-Szczygieł B, Szlauer B, Korcz-Ondrzejek B, Sieklucki J, Pleśniak R, Ruszała A, Postawa-Kłosińska B, Citko J, Lachowicz-Wawrzyniak A, Musialik J, Jezierska E, Dobracki W, Dobracka B, Hałubiec J, Krygier R, Strokowska A, Chomczyk W, Witczak-Malinowska K.
PMID: 28856278
Clin Exp Hepatol. 2016 Dec;2(4):138-143. doi: 10.5114/ceh.2016.63870. Epub 2016 Nov 28.

THE AIM OF THE STUDY: Was to analyze the efficacy achieved with regimens available for chronic hepatitis C (CHC) in Poland between 2013 and 2016.MATERIAL AND METHODS: Data were collected from 29 centers and included 6786 patients with available...

Cite
Flisiak R, Pogorzelska J, Berak H, et al. Efficacy of HCV treatment in Poland at the turn of the interferon era - the EpiTer study. Clin Exp Hepatol. 2016;2(4):138-143doi: 10.5114/ceh.2016.63870.
Flisiak, R., Pogorzelska, J., Berak, H., Horban, A., Orłowska, I., Simon, K., Tuchendler, E., Madej, G., Piekarska, A., Jabłkowski, M., Deroń, Z., Mazur, W., Kaczmarczyk, M., Janczewska, E., Pisula, A., Smykał, J., Nowak, K., Matukiewicz, M., Halota, W., Wernik, J., Sikorska, K., Mozer-Lisewska, I., Rozpłochowski, B., Garlicki, A., Tomasiewicz, K., Krzowska-Firych, J., Baka-Ćwierz, B., Kryczka, W., Zarębska-Michaluk, D., Olszok, I., Boroń-Kaczmarska, A., Sobala-Szczygieł, B., Szlauer, B., Korcz-Ondrzejek, B., Sieklucki, J., Pleśniak, R., Ruszała, A., Postawa-Kłosińska, B., Citko, J., Lachowicz-Wawrzyniak, A., Musialik, J., Jezierska, E., Dobracki, W., Dobracka, B., Hałubiec, J., Krygier, R., Strokowska, A., Chomczyk, W., & Witczak-Malinowska, K. (2016). Efficacy of HCV treatment in Poland at the turn of the interferon era - the EpiTer study. Clinical and experimental hepatology, 2(4), 138-143. https://doi.org/10.5114/ceh.2016.63870
Flisiak, Robert, et al. "Efficacy of HCV treatment in Poland at the turn of the interferon era - the EpiTer study." Clinical and experimental hepatology vol. 2,4 (2016): 138-143. doi: https://doi.org/10.5114/ceh.2016.63870
Flisiak R, Pogorzelska J, Berak H, Horban A, Orłowska I, Simon K, Tuchendler E, Madej G, Piekarska A, Jabłkowski M, Deroń Z, Mazur W, Kaczmarczyk M, Janczewska E, Pisula A, Smykał J, Nowak K, Matukiewicz M, Halota W, Wernik J, Sikorska K, Mozer-Lisewska I, Rozpłochowski B, Garlicki A, Tomasiewicz K, Krzowska-Firych J, Baka-Ćwierz B, Kryczka W, Zarębska-Michaluk D, Olszok I, Boroń-Kaczmarska A, Sobala-Szczygieł B, Szlauer B, Korcz-Ondrzejek B, Sieklucki J, Pleśniak R, Ruszała A, Postawa-Kłosińska B, Citko J, Lachowicz-Wawrzyniak A, Musialik J, Jezierska E, Dobracki W, Dobracka B, Hałubiec J, Krygier R, Strokowska A, Chomczyk W, Witczak-Malinowska K. Efficacy of HCV treatment in Poland at the turn of the interferon era - the EpiTer study. Clin Exp Hepatol. 2016 Dec;2(4):138-143. doi: 10.5114/ceh.2016.63870. Epub 2016 Nov 28. PMID: 28856278; PMCID: PMC5497429.
Copy Download .nbib Format: NLM
ALMOND MILK: A POTENTIAL THERAPEUTIC WEAPON AGAINST COW’S MILK PROTEIN ALLERGY.

Journal of biological regulators and homeostatic agents

Cuppari C, Manti S, Salpietro A, Dugo G, Gitto E, Arrigo T, Sturiale M, Salpietro C.
PMID: 26634581
J Biol Regul Homeost Agents. 2015 Apr-Jun;29(2):8-12.

Food allergy is defined as an adverse health effect arising from a specific immune response that occurs reproducibly following exposure to a given food. Cow’s milk protein allergy results from an immunological reaction to one or more milk proteins....

Cite
Cuppari C, Manti S, Salpietro A, et al. ALMOND MILK: A POTENTIAL THERAPEUTIC WEAPON AGAINST COW’S MILK PROTEIN ALLERGY. J Biol Regul Homeost Agents. 2015;29(2):8-12
Cuppari, C., Manti, S., Salpietro, A., Dugo, G., Gitto, E., Arrigo, T., Sturiale, M., & Salpietro, C. (2015). ALMOND MILK: A POTENTIAL THERAPEUTIC WEAPON AGAINST COW’S MILK PROTEIN ALLERGY. Journal of biological regulators and homeostatic agents, 29(2), 8-12.
Cuppari, C, et al. "ALMOND MILK: A POTENTIAL THERAPEUTIC WEAPON AGAINST COW’S MILK PROTEIN ALLERGY." Journal of biological regulators and homeostatic agents vol. 29,2 (2015): 8-12.
Cuppari C, Manti S, Salpietro A, Dugo G, Gitto E, Arrigo T, Sturiale M, Salpietro C. ALMOND MILK: A POTENTIAL THERAPEUTIC WEAPON AGAINST COW’S MILK PROTEIN ALLERGY. J Biol Regul Homeost Agents. 2015 Apr-Jun;29(2):8-12. PMID: 26634581.
Copy Download .nbib Format: NLM
HIGH-MOBILITY GROUP BOX 1 IN ALLERGIC AND NON ALLERGIC UPPER AIRWAY INFLAMMATION.

Journal of biological regulators and homeostatic agents

Chirico V, Lacquaniti A, Vinci S, Piraino B, Manti S, Marseglia L, Salpietro A, Gitto E, Arrigo T, Salpietro C, Cuppari C.
PMID: 26634588
J Biol Regul Homeost Agents. 2015 Apr-Jun;29(2):55-7.

High mobility group box 1, an evolutionary ancient protein conserved in the eukaryotic kingdom, exerts intra- and extra- cellular functions, orchestrating a homeostatic defensive response in challenged tissues. Its action associated with various inflammatory cells is essential for the...

Cite
Chirico V, Lacquaniti A, Vinci S, et al. HIGH-MOBILITY GROUP BOX 1 IN ALLERGIC AND NON ALLERGIC UPPER AIRWAY INFLAMMATION. J Biol Regul Homeost Agents. 2015;29(2):55-7
Chirico, V., Lacquaniti, A., Vinci, S., Piraino, B., Manti, S., Marseglia, L., Salpietro, A., Gitto, E., Arrigo, T., Salpietro, C., & Cuppari, C. (2015). HIGH-MOBILITY GROUP BOX 1 IN ALLERGIC AND NON ALLERGIC UPPER AIRWAY INFLAMMATION. Journal of biological regulators and homeostatic agents, 29(2), 55-7.
Chirico, V, et al. "HIGH-MOBILITY GROUP BOX 1 IN ALLERGIC AND NON ALLERGIC UPPER AIRWAY INFLAMMATION." Journal of biological regulators and homeostatic agents vol. 29,2 (2015): 55-7.
Chirico V, Lacquaniti A, Vinci S, Piraino B, Manti S, Marseglia L, Salpietro A, Gitto E, Arrigo T, Salpietro C, Cuppari C. HIGH-MOBILITY GROUP BOX 1 IN ALLERGIC AND NON ALLERGIC UPPER AIRWAY INFLAMMATION. J Biol Regul Homeost Agents. 2015 Apr-Jun;29(2):55-7. PMID: 26634588.
Copy Download .nbib Format: NLM
In Reply to Samaratunga et al.

International journal of radiation oncology, biology, physics

Zietman A, Smith J, Klein E, Droller M, Dasgupta P, Catto J.
PMID: 27869088
Int J Radiat Oncol Biol Phys. 2016 Dec 01;96(5):1127-1128. doi: 10.1016/j.ijrobp.2016.08.027.

No abstract available.

Cite
Zietman A, Smith J, Klein E, et al. In Reply to Samaratunga et al. Int J Radiat Oncol Biol Phys. 2016;96(5):1127-1128doi: 10.1016/j.ijrobp.2016.08.027.
Zietman, A., Smith, J., Klein, E., Droller, M., Dasgupta, P., & Catto, J. (2016). In Reply to Samaratunga et al. International journal of radiation oncology, biology, physics, 96(5), 1127-1128. https://doi.org/10.1016/j.ijrobp.2016.08.027
Zietman, Anthony, et al. "In Reply to Samaratunga et al." International journal of radiation oncology, biology, physics vol. 96,5 (2016): 1127-1128. doi: https://doi.org/10.1016/j.ijrobp.2016.08.027
Zietman A, Smith J, Klein E, Droller M, Dasgupta P, Catto J. In Reply to Samaratunga et al. Int J Radiat Oncol Biol Phys. 2016 Dec 01;96(5):1127-1128. doi: 10.1016/j.ijrobp.2016.08.027. PMID: 27869088.
Copy Download .nbib Format: NLM
Treatment of acute myeloid leukemia with 20-30% bone marrow blasts.

Mediterranean journal of hematology and infectious diseases

Maurillo L, Buccisano F, Del Principe MI, Sarlo C, Di Caprio L, Ditto C, Giannotti F, Nasso D, Ceresoli E, Postorino M, Refrigeri M, Amadori S, Venditti A.
PMID: 23795270
Mediterr J Hematol Infect Dis. 2013 Jun 03;5(1):e2013032. doi: 10.4084/MJHID.2013.032. Print 2013.

The transition of patients with ≥20% 30% BM blast. These controversies are even more manifest when it comes to elderly patients in whom concern for intensive chemotherapy (IC) related toxicity is the critical determinant for the therapeutic choice. In...

Cite
Maurillo L, Buccisano F, Del Principe MI, et al. Treatment of acute myeloid leukemia with 20-30% bone marrow blasts. Mediterr J Hematol Infect Dis. 2013;5(1):e2013032doi: 10.4084/MJHID.2013.032.
Maurillo, L., Buccisano, F., Del Principe, M. I., Sarlo, C., Di Caprio, L., Ditto, C., Giannotti, F., Nasso, D., Ceresoli, E., Postorino, M., Refrigeri, M., Amadori, S., & Venditti, A. (2013). Treatment of acute myeloid leukemia with 20-30% bone marrow blasts. Mediterranean journal of hematology and infectious diseases, 5(1), e2013032. https://doi.org/10.4084/MJHID.2013.032
Maurillo, Luca, et al. "Treatment of acute myeloid leukemia with 20-30% bone marrow blasts." Mediterranean journal of hematology and infectious diseases vol. 5,1 (2013): e2013032. doi: https://doi.org/10.4084/MJHID.2013.032
Maurillo L, Buccisano F, Del Principe MI, Sarlo C, Di Caprio L, Ditto C, Giannotti F, Nasso D, Ceresoli E, Postorino M, Refrigeri M, Amadori S, Venditti A. Treatment of acute myeloid leukemia with 20-30% bone marrow blasts. Mediterr J Hematol Infect Dis. 2013 Jun 03;5(1):e2013032. doi: 10.4084/MJHID.2013.032. Print 2013. PMID: 23795270; PMCID: PMC3684350.
Copy Download .nbib Format: NLM
Sentinel Node Mapping in Endometrial Cancer By Using Hysteroscopic Injection of Indocyanine Green and Laparoscopic Near-Infrared Fluorescence Imaging: A Preliminary Experience.

Journal of minimally invasive gynecology

Martinelli F, Ditto A, Bogani G, Chiappa V, Lorusso D, Raspagliesi F.
PMID: 27679230
J Minim Invasive Gynecol. 2015 Nov-Dec;22(6):S4. doi: 10.1016/j.jmig.2015.08.017. Epub 2015 Oct 15.

No abstract available.

Cite
Martinelli F, Ditto A, Bogani G, et al. Sentinel Node Mapping in Endometrial Cancer By Using Hysteroscopic Injection of Indocyanine Green and Laparoscopic Near-Infrared Fluorescence Imaging: A Preliminary Experience. J Minim Invasive Gynecol. 2015;22(6):S4doi: 10.1016/j.jmig.2015.08.017.
Martinelli, F., Ditto, A., Bogani, G., Chiappa, V., Lorusso, D., & Raspagliesi, F. (2015). Sentinel Node Mapping in Endometrial Cancer By Using Hysteroscopic Injection of Indocyanine Green and Laparoscopic Near-Infrared Fluorescence Imaging: A Preliminary Experience. Journal of minimally invasive gynecology, 22(6), S4. https://doi.org/10.1016/j.jmig.2015.08.017
Martinelli, F, et al. "Sentinel Node Mapping in Endometrial Cancer By Using Hysteroscopic Injection of Indocyanine Green and Laparoscopic Near-Infrared Fluorescence Imaging: A Preliminary Experience." Journal of minimally invasive gynecology vol. 22,6 (2015): S4. doi: https://doi.org/10.1016/j.jmig.2015.08.017
Martinelli F, Ditto A, Bogani G, Chiappa V, Lorusso D, Raspagliesi F. Sentinel Node Mapping in Endometrial Cancer By Using Hysteroscopic Injection of Indocyanine Green and Laparoscopic Near-Infrared Fluorescence Imaging: A Preliminary Experience. J Minim Invasive Gynecol. 2015 Nov-Dec;22(6):S4. doi: 10.1016/j.jmig.2015.08.017. Epub 2015 Oct 15. PMID: 27679230.
Copy Download .nbib Format: NLM
A Case of "Surra" in Manipur.

The Indian medical gazette

Catto J.
PMID: 29006474
Ind Med Gaz. 1908 Jul;43(7):259-260.

No abstract available.

Cite
Catto J. A Case of "Surra" in Manipur. Ind Med Gaz. 1908;43(7):259-260
Catto, J. (1908). A Case of "Surra" in Manipur. The Indian medical gazette, 43(7), 259-260.
Catto, John. "A Case of "Surra" in Manipur." The Indian medical gazette vol. 43,7 (1908): 259-260.
Catto J. A Case of "Surra" in Manipur. Ind Med Gaz. 1908 Jul;43(7):259-260. PMID: 29006474; PMCID: PMC5182928.
Copy Download .nbib Format: NLM
Dose-dependent effects of mTOR inhibition on weight and mitochondrial disease in mice.

Frontiers in genetics

Johnson SC, Yanos ME, Bitto A, Castanza A, Gagnidze A, Gonzalez B, Gupta K, Hui J, Jarvie C, Johnson BM, Letexier N, McCanta L, Sangesland M, Tamis O, Uhde L, Van Den Ende A, Rabinovitch PS, Suh Y, Kaeberlein M.
PMID: 26257774
Front Genet. 2015 Jul 22;6:247. doi: 10.3389/fgene.2015.00247. eCollection 2015.

Rapamycin extends lifespan and attenuates age-related pathologies in mice when administered through diet at 14 parts per million (PPM). Recently, we reported that daily intraperitoneal injection of rapamycin at 8 mg/kg attenuates mitochondrial disease symptoms and progression in the...

Cite
Johnson SC, Yanos ME, Bitto A, et al. Dose-dependent effects of mTOR inhibition on weight and mitochondrial disease in mice. Front Genet. 2015;6:247doi: 10.3389/fgene.2015.00247.
Johnson, S. C., Yanos, M. E., Bitto, A., Castanza, A., Gagnidze, A., Gonzalez, B., Gupta, K., Hui, J., Jarvie, C., Johnson, B. M., Letexier, N., McCanta, L., Sangesland, M., Tamis, O., Uhde, L., Van Den Ende, A., Rabinovitch, P. S., Suh, Y., & Kaeberlein, M. (2015). Dose-dependent effects of mTOR inhibition on weight and mitochondrial disease in mice. Frontiers in genetics, 6247. https://doi.org/10.3389/fgene.2015.00247
Johnson, Simon C, et al. "Dose-dependent effects of mTOR inhibition on weight and mitochondrial disease in mice." Frontiers in genetics vol. 6 (2015): 247. doi: https://doi.org/10.3389/fgene.2015.00247
Johnson SC, Yanos ME, Bitto A, Castanza A, Gagnidze A, Gonzalez B, Gupta K, Hui J, Jarvie C, Johnson BM, Letexier N, McCanta L, Sangesland M, Tamis O, Uhde L, Van Den Ende A, Rabinovitch PS, Suh Y, Kaeberlein M. Dose-dependent effects of mTOR inhibition on weight and mitochondrial disease in mice. Front Genet. 2015 Jul 22;6:247. doi: 10.3389/fgene.2015.00247. eCollection 2015. PMID: 26257774; PMCID: PMC4510413.
Copy Download .nbib Format: NLM
Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy.

Leukemia research and treatment

Sarlo C, Buccisano F, Maurillo L, Cefalo M, Di Caprio L, Cicconi L, Ditto C, Ottaviani L, Di Veroli A, Del Principe MI, Grasso MA, Nasso D, De Santis G, Amadori S, Venditti A.
PMID: 23738080
Leuk Res Treatment. 2013;2013:705714. doi: 10.1155/2013/705714. Epub 2013 Apr 28.

We explored the safety and efficacy of bortezomib given as single agent in patients with untreated or relapsed/refractory acute myeloid leukemia (AML), unfit for conventional chemotherapy. Fourteen patients were treated with bortezomib 1.5 mg/m(2) administered twice weekly for two...

Cite
Sarlo C, Buccisano F, Maurillo L, et al. Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy. Leuk Res Treatment. 2013;2013:705714doi: 10.1155/2013/705714.
Sarlo, C., Buccisano, F., Maurillo, L., Cefalo, M., Di Caprio, L., Cicconi, L., Ditto, C., Ottaviani, L., Di Veroli, A., Del Principe, M. I., Grasso, M. A., Nasso, D., De Santis, G., Amadori, S., & Venditti, A. (2013). Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy. Leukemia research and treatment, 2013705714. https://doi.org/10.1155/2013/705714
Sarlo, Chiara, et al. "Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy." Leukemia research and treatment vol. 2013 (2013): 705714. doi: https://doi.org/10.1155/2013/705714
Sarlo C, Buccisano F, Maurillo L, Cefalo M, Di Caprio L, Cicconi L, Ditto C, Ottaviani L, Di Veroli A, Del Principe MI, Grasso MA, Nasso D, De Santis G, Amadori S, Venditti A. Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy. Leuk Res Treatment. 2013;2013:705714. doi: 10.1155/2013/705714. Epub 2013 Apr 28. PMID: 23738080; PMCID: PMC3655652.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 233 entries